ESCHERICHIA COLI
Fibromyalgia
University of Alabama at Birminghamother_biologicalPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Fibromyalgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Cukurova University | Phase 4 | BBB |
Pregabalin Yung Shin Pharm. Ind. Co., Ltd. | Phase 4 | BB |
PIPERAZINE, 1-(BIS(4-FLUOROPHENYL)METHYL)-4-(3-PHENYL-2-PROPENYL)-, (E)- Taipei Veterans General Hospital, Taiwan | Phase 4 | BB |
LIDOCAINE Peking University Third Hospital | Phase 2 | BB |
ds-5565 Daiichi Sankyo | Phase 3 | B |
View all 36 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →